WO2006025069A2 - Tricyclic pyrazole derivatives as cannabinoid receptor modulators - Google Patents
Tricyclic pyrazole derivatives as cannabinoid receptor modulators Download PDFInfo
- Publication number
- WO2006025069A2 WO2006025069A2 PCT/IN2005/000237 IN2005000237W WO2006025069A2 WO 2006025069 A2 WO2006025069 A2 WO 2006025069A2 IN 2005000237 W IN2005000237 W IN 2005000237W WO 2006025069 A2 WO2006025069 A2 WO 2006025069A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloro
- groups
- pharmaceutically acceptable
- carboxylic acid
- phenyl
- Prior art date
Links
- 0 C[C@](C1)[C@@]1[n]1nc(C(O)=O)c2c1C(CCCCC1)C1***2 Chemical compound C[C@](C1)[C@@]1[n]1nc(C(O)=O)c2c1C(CCCCC1)C1***2 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to novel compounds of general formula (I), their regioisomers, tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
- the present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
- Cannabinoids are present in Indian hemp Cannabis sativa and have been well known for their medicinal properties for ages. Cannabinoids as a therapeutic agents is however a recent phenomenon. (Williamson E. M. & Evans E. J. Drugs 2000 Dec; 60(6): 1303-14) Research in this area over the last decade have provided very important information on the cannabinoid receptors and their agonists and antagonists. Development of central Cannabinoid receptor ligands with lower lipophilicity.( J. Med. Chem.
- Tricyclic benzopyrazole derivatives as cyclooxygenase-2 (COX-2) inhibitors have been disclosed in WO 9609304, which is also incorporated herein as reference.
- the compounds of the present invention mimic the actions of the cannabinoids making them useful for preventing or reversing the symptoms that can be treated with cannabis, some of its derivatives, and synthetic cannabinoids in a human or other mammalian subject.
- the compounds of the present invention are selective antagonists of the cannabis CBi-receptor.
- the object of the present invention thus is to provide novel compounds of general formula (I), their tautomeric forms, their regioisomers, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them or their mixtures and their use in medicine.
- compositions containing compounds of general formula (I), their tautomeric forms, their regioisomers, their pharmaceutically acceptable salts and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture are provided.
- a method of treatment of diseases which can be treated or whose symptoms can be reversed with cannabis or their derivatives both natural and synthetic, by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable compositions to the mammals.
- novel compounds of the present invention are defined by the general formula (I) below:
- 'Ar' represents single or fused groups selected from aryl, aralkyl, heterocyclyl, heteroaryl, heterocyclyl(C 1 -C 12 )alkyl & heteroar(Ci-Ci 2 )alkyl group, each of them independently may optionally be substituted;
- 'A' represents optionally substituted heteroaromatic groups
- X' is selected from -CH 2 -, O, S, SO, SO 2 , or NR', where R' represents H, optionally substituted groups selected from linear or branched alkyl and cycloalkyl groups and, m & n represents integers such that 1 ⁇ m+n ⁇ 3; or
- X' may be selected from O, S, SO,
- R' represents H, optionally substituted groups selected from linear or branched alkyl, and cycloalkyl groups and m & n represents integers such that
- X' may be selected from -CH 2 -, O, S, SO, SO 2 , or NR', where R' represents H, optionally substituted groups selected from linear or branched alkyl and cycloalkyl groups and m & n represents integers such that 1 ⁇ m+n ⁇ 3; or
- X' may be selected from
- R' represents H, optionally substituted groups selected from linear or branched alkyl and cycloalkyl groups and m & n represents integers such that 1 ⁇ m+n ⁇ 3; or R 1 represents O, S, or the group represented by N-Q, where Q represents H, substituted or unsubstituted groups selected from alkyl, aralkyl, aryl, heteroaryl or heterocyclic groups or the group represented by SO 2 R", where R" represents H, -OH, halogen or substituted or unsubstituted groups selected from alkyl, aralkyl, aryl, heteroaryl or heterocyclic or alicyclic groups; R 2 is either H or (C 1 -C 6 ) alkyl; R 3 is — NRaRbRc O r -NRbR 0 where Ra is (C 1 - C6)alkyl or Ra forms a bridge containing 1-2
- Rb and R 0 represents optionally substituted groups selected from alkyl, aralkyl or alkenyl or R b & R 0 together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic or heteroaromatic radical which may be optionally substituted and may be fused;
- the substituents on 'A' may be selected from hydroxyl, oxo, halo, thio, nitro, amino, cyano, formyl, optionally substituted groups selected from linear or branched alkyl, haloalkyl, perhaloalkyl, alkoxy, haloalkoxy, perhaloalkoxy, alkenyl, alkynyl, alkoxy, alkenoxy, acyl, acyloxy, acylamino, monosubstituted or disubstituted amino, carboxylic acid and its derivatives such as esters and amides, carbonylamino, hydroxyalkyl, aminoalkyl, alkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, alkoxyamino, hydroxyl amino groups; preferably, the substituents on 'A' may be selected from halogen,
- the substituents on 'Ar' may be selected from hydroxy, halo, thio, nitro, amino, cyano, formyl, or optionally substituted groups selected from amidino, linear or branched alkyl, haloalkyl, perhaloalkyl, alkoxy, haloalkoxy, perhaloalkoxy, alkenyl, alkynyl, alkoxy, alkenoxy, monosubstituted or disubstituted amino, carboxylic acid and its derivatives such as esters and amides, carbonylamino, hydroxyalkyl, aminoalkyl, alkoxyalkyl, alkylthio, thioalkyl, alkylsulfonylamino, alkylsulfonyloxy, alkoxycarbonylamino, hydroxyl amino, sulfenyl derivatives, sulfonyl derivatives, sulfonic acid and its derivatives; preferably the substituents on
- radicals described above may be selected from: - the "alkyl” group used either alone or in combination with other radicals, denotes a linear or branched radical containing one to eight carbons, selected from methyl, ethyl, «-propyl, wo-propyl, w-butyl, sec-butyl, tert-butyl, amyl, f-amyl, «-pentyl, n- hexyl, rao-hexyl, heptyl, octyl and the like; - the "alkenyl” group used either alone or in combination with other radicals, is selected from a radical containing from two to twelve carbons, more preferably groups selected from vinyl, allyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4- pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hex
- cycloalkyl or "alicyclic” group used either alone or in combination with other radicals is selected from a cyclic radical containing three to seven carbons, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like;
- cycloalkenyl used either alone or in combination with other radicals, are preferably selected from cyclopropenyl, 1-cyclobutenyl, 2-cylobutenyl, 1- cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, and the like;
- the "alkoxy” group used either alone or in combination with other radicals is selected from groups containing an alkyl radical, as
- haloalkyl is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as perhaloalkyl, more preferably, perfluoro(Ci-C 6 )alkyl such as fluoromethyl, difluoromethyl,, trifluoromethyl, fluoroethyl, difluoro ethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups;
- perhaloalkyl more preferably, perfluoro(Ci-C 6 )alkyl such as fluoromethyl, difluoromethyl,, trifluoromethyl, fluoroethyl, difluoro ethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups;
- haloalkoxy is selected from suitable haloalkyl, as defined above, directly attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy, fluoroethoxy chloroethoxy and the like;
- the "perhaloalkoxy” group is selected from a suitable perha ⁇ oalkyl radical, as defined above, directly attached to an oxygen atom, more preferably groups selected from trifluoromethoxy, trifluoroethoxy, and the like;
- the "aryl” or “aromatic” group used either alone or in combination with other radicals is selected from a suitable aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused, more preferably the groups are selected from phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl, and the like;
- the "heterocyclyl” or “heterocyclic” group used either alone or in combination with other radicals is selected from suitable saturated, partially saturated or unsaturated aromatic or non aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, a
- heteroaryl or “heteroaromatic” group used either alone or in combination with other radicals, is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinoliny
- heteroaryloxy -the groups “heteroaryloxy”, “heteroaralkoxy”, “heterocycloxy”, “heterocylylalkoxy” are selected from suitable heteroaryl, heteroarylalkyl, heterocyclyl, heterocylylalkyl groups respectively, as defined above, attached to an oxygen atom;
- acyl group used either alone or in combination with other radicals is selected from a radical containing one to eight carbons, more preferably selected from formyl, acetyl, propanoyl, butanoyl, wo-butanoyl, pentanoyl, hexanoyl, heptanoyl, benzoyl and the like, which may be substituted;
- acyloxy used either alone or in combination with other radicals, is selected from a suitable acyl group, as defined above, directly attached to an oxygen atom, more preferably such groups are selected from acetyloxy, propionyloxy, butanoyloxy, w ⁇ -butanoyloxy, benzoyloxy and the like;
- acylamino used either alone or in combination with other radicals, is selected from a suitable acyl group as defined earlier, attached to an amino radical, more preferably such groups are selected from CH 3 CONH, C 2 HsCONH, C 3 H 7 CONH, C 4 H 9 CONH, C 6 H 5 CONH and the like, which may be substituted, - the "mono-substituted amino” group used either alone or in combination with other radicals, represents an amino group substituted with one group selected from (C 1 - Ce)alkyl, substituted alkyl, aryl, substituted aryl or arylalkyl groups as defined earlier, more preferably such groups are selected from methylamine, ethylamine, n- propylamine, w-butylamine, w-pentylamine and the like; - the 'disubstituted amino" group used either alone or in combination with other radicals, represents an amino group, substituted with two radicals that may be same or
- - the "carboxylic acid” group used alone or in combination with other radicals, denotes a -COOH group, and includes derivatives of carboxylic acid such as esters and amides;
- ester moieties are selected from alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, and the like, which may optionally be substituted; aryloxycarbonyl group such as phenoxycarbonyl, napthyloxycarbonyl, and the like, which may optionally be substituted; aralkoxycarbonyl group such as benzyloxycarbonyl, phenethyloxycarbonyl, napthylmethoxycarbonyl, and the like, which may optionally be substituted; heteroaryloxycarbonyl, heteroaralkoxycarbonyl, wherein the heteroaryl group, is as defined above, which may optionally be substituted; heterocyclyloxycarbonyl, where the heterocyclic group, as defined earlier, which may optionally be substituted;
- the "aminocarbonyl” group used either alone or in combination with other radicals may be selected from 'aminocarbonyl', 'aminocarbonylalkyl", "n- alkylaminocarbonyl", “N-arylaminocarbonyl”, “N,N-dialkylaminocarbonyl”, “N- alkyl-N-arylaminocarbonyl", “N-alkyl-N-hydroxyaminocarbonyl", and "N-alkyl- N-hydroxyaminocarbonylalkyl", each of them being optionally substituted.
- N-alkylaminocabonyl and “N,N-dialkylamino carbonyl” denotes aminocarbonyl radicals, as defined above, which have been substituted with one alkyl radical and with two alkyl radicals, respectively. Preferred are “lower alkylaminocarbonyl” having lower alkyl radicals as described above attached to aminocarbonyl radical.
- N-arylaminocarbonyl and “N-alkyl-N- arylaminocarbonyl” denote amiocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl, and one aryl radical.
- aminocarbonylalkyl includes alkyl radicals substituted with aminocarbonyl radicals;
- hydroxyalkyl used either alone or in combination with other radicals, is selected from an alkyl group, as defined above, substituted with one or more hydroxy radicals, more preferably the groups are selected from hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl and the like;
- aminoalkyl used alone or in combination with other radicals, denotes an amino (-NH 2 ) moiety attached to an alkyl radical, as defined above, which may be substituted, such as mono- and di-substituted aminoalkyl.
- alkylamino used herein, alone or in combination with other radicals, denotes an alkyl radical, as defined above, attached to an amino group, which may be substituted, such as mono- and di-substituted alkylamino;
- alkoxyalkyl denotes an alkoxy group, as defined above, attached to an alkyl group as defined above, more preferably the groups may be selected from methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like;
- alkylthio used either alone or in combination with other radicals, denotes a straight or branched or cyclic monovalent substituent comprising an alkyl group as defined above, linked through a divalent sulfur atom having a free valence bond from the sulfur atom, more preferably the groups may be selected from methylthio, ethylthio, propylthio, butylthio, pentylthio and the like or cyclic alkylthio selected from cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio and the like, which may be optionally substituted;
- the "thioalkyl” group used either alone or in combination with other radicals denotes an alkyl group, as defined above, attached to a group of formula -SR', where R' represents hydrogen, alkyl or aryl group, e.g.
- alkoxycarbonylamino used alone or in combination with other radicals, is selected from a suitable alkoxycarbonyl group, as defined above, attached to an amino group, more preferably methoxycarbonylamino, ethoxycarbonylamino, and the like;
- the "aminocarbonylamino”, “alkylaminocarbonylamino”, “dialkylaminocarbonylamino” groups used alone or in combination with other radicals is a carbonylamino (-CONH 2 ) group, attached to amino(NH2), alkylamino group or dialkylamino group respectively, where alkyl group is as defined above;
- the "alkylamidino” group represents an alkyl radical, as described
- hydrazino used either alone or in combination with other radicals, represents a group of the formula -NHNH-, suitably substituted with other radicals, selected from those described above such as an alkyl hydrazino, where an alkyl group, as defined above is attached to a hydrazino group;
- alkoxyamino used either alone or in combination with other radicals, represents a suitable alkoxy group as defined above, attached to an amino group;
- hydroxyamino used either alone or in combination with other radicals, represents a -NHOH moiety, and may be optionally substituted with suitable groups selected from those described above;
- sulfenyl group or “sulfenyl derivatives” used alone or in combination with other radicals, represents a bivalent group, -SO- or R x SO, where R x is an optionally substituted alkyl, aryl, heteroaryl, heterocyclyl, group selected from those described above;
- the groups may be selected from “alkylsulfonyl” wherein suitable alkyl radicals, selected from those defined above, is attached to a sulfonyl radical, such as methylsulfonyl, ethylsulfonyl, propylsulfonyl and the like, "arylsulfonyl” wherein an aryl radical, as defined above, is attached to a sulfonyl radical, such as phenylsulfonyl and the like.
- Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
- Particularly useful compounds of the present invention are:
- 8-chloro-l-(4-chloro-phenyl)-4 5-dihydro-lH-6-oxa-l, 2-diaza-benzo [e] azulene-3-carboxylic acid pyrrolidin-1-ylamide and its pharmaceutically acceptable salts
- 8-chloro-l-(4-chloro-phenyl)-4 5-dihydro-lH-6-oxa-l, 2-diaza-benzo [e] azulene-3-carboxylic acid morpholin-4-ylamide and its pharmaceutically acceptable salts
- Compound of formula 2 by suitable modification of similar processes described earlier in the art [Chem. Pharm. Bull. 2002, 50, 1109-1113].
- Compound of formula 4 may be prepared by refiuxing 2 with suitable substituted hydrazine hydrochloride of formula 3, where 'Ar' is as defined earlier, in suitable solvents such as MeOH, EtOH, propanol, isopropanol, butanol, /-butanol, acetic acid and the like or mixtures thereof.
- the compound of formula 5 may optionally, after conversion to its corresponding acid chloride be treated with suitable compounds of formula 6, where 'Q' is as defined earlier, in solvents selected from triethyl amine, DMSO, DMF, diisopropyl ethyl amine and the like or mixtures thereof to obtain the compounds of formula 7.
- the compounds of formula (I) may be optionally converted to their suitable pharmaceutically acceptable salts by suitable modifications of techniques and processes known to persons skilled in the art.
- any reactive group in the substrate molecule may be protected, according to conventional chemical practice.
- Suitable protecting groups in any of the above mentioned reactions are those used conventionally in the art.
- the methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
- the novel compounds of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients as are well known.
- the compounds of Formula (I) or pharmaceutical compositions containing them may be administered either by oral, topical or parenteral administration.
- the pharmaceutical composition is provided by employing conventional techniques.
- the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula (I) according to this invention.
- the quantity of active component, that is, the compounds of formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5 % to 90 % by weight of the composition.
- Compound 12 Hydrochloride salt of 8-chloro-l-(4-chloro-phenyl)-4, 5-dihydro-lH-6-oxa-l, 2- diaza-benzo [e] azulene-3-carboxylic acid piperidin-1-ylaniide.
- Compound 18 Hydrochloride salt of 8-Chloro-l-(2, 4-dichloro-phenyl)-4, 5-dihydro-lH-6, 7- dithia-1, 2-diaza-cyclopenta [e] azulene-3-carboxylic acid piperidin-1-ylamide.
- Compound 19 Hydrochloride salt of 7-Chloro-l-(2, 4-dichloro-phenyl)-l, 5-dihydro-4, 6- dithia-1, 2-diaza-as-indacene-3-carboxylic acid piperidin-1-ylamide.
- Table 1 Effect of representative compounds on the intake of 5 % sucrose solution in animal model.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AP2007003880A AP2228A (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators. |
EA200700246A EA011307B1 (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
MX2007000491A MX2007000491A (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators. |
JP2007520976A JP2008505965A (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modifiers |
EP05815697A EP1781668A2 (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
CA2586011A CA2586011C (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
BRPI0513104-9A BRPI0513104A (en) | 2004-07-12 | 2005-07-08 | compound, pharmaceutical composition, method for treating cannabinoid receptor-associated diseases, medicament for treating / reducing cannabinoid receptor-associated diseases, use of compound, process for preparing compound and intermediate |
AU2005278781A AU2005278781B2 (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
NZ552670A NZ552670A (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
US11/632,236 US8030345B2 (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
IL180637A IL180637A0 (en) | 2004-07-12 | 2007-01-10 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
TNP2007000006A TNSN07006A1 (en) | 2004-07-12 | 2007-01-11 | Novel heterocyclic compounds |
NO20070299A NO20070299L (en) | 2004-07-12 | 2007-01-17 | Novel heterocyclic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN745/MUM/2004 | 2004-07-12 | ||
IN745MU2004 | 2004-07-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006025069A2 true WO2006025069A2 (en) | 2006-03-09 |
WO2006025069A3 WO2006025069A3 (en) | 2006-04-27 |
WO2006025069A8 WO2006025069A8 (en) | 2007-03-15 |
Family
ID=35636669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2005/000237 WO2006025069A2 (en) | 2004-07-12 | 2005-07-08 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
Country Status (20)
Country | Link |
---|---|
US (2) | US8030345B2 (en) |
EP (2) | EP2343302A1 (en) |
JP (1) | JP2008505965A (en) |
KR (1) | KR20070041717A (en) |
CN (1) | CN101014605A (en) |
AP (1) | AP2228A (en) |
AU (1) | AU2005278781B2 (en) |
BR (1) | BRPI0513104A (en) |
CA (1) | CA2586011C (en) |
EA (1) | EA011307B1 (en) |
EC (1) | ECSP077167A (en) |
GE (1) | GEP20094682B (en) |
IL (1) | IL180637A0 (en) |
MX (1) | MX2007000491A (en) |
NO (1) | NO20070299L (en) |
NZ (2) | NZ580387A (en) |
TN (1) | TNSN07006A1 (en) |
UA (1) | UA88910C2 (en) |
WO (1) | WO2006025069A2 (en) |
ZA (1) | ZA200700162B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8778950B2 (en) | 2009-08-28 | 2014-07-15 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US9458136B2 (en) | 2011-02-25 | 2016-10-04 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
US9492447B2 (en) | 2011-02-25 | 2016-11-15 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US11084789B2 (en) | 2016-01-14 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030345B2 (en) * | 2004-07-12 | 2011-10-04 | Cadila Healthcare Limited | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
US10351576B2 (en) * | 2015-04-30 | 2019-07-16 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors |
KR20200115597A (en) * | 2018-01-29 | 2020-10-07 | 카딜라 핼쓰캐어 리미티드 | Heterocyclic compounds useful as antibacterial agents |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3260721A (en) * | 1962-04-10 | 1966-07-12 | American Cyanamid Co | Heterocyclic derivatives of yohimbe alkaloids |
DK7779A (en) * | 1978-01-16 | 1979-07-17 | Sandoz Ag | PROCEDURE FOR THE PREPARATION OF PNENICILLINS OR CEPHALOSPORINES |
EP0122952B1 (en) | 1983-04-22 | 1987-10-28 | Mitsubishi Rayon Co., Ltd. | Apparatus for measuring gas partial pressure in living body |
FR2713225B1 (en) | 1993-12-02 | 1996-03-01 | Sanofi Sa | Substituted N-piperidino-3-pyrazolecarboxamide. |
FR2692575B1 (en) | 1992-06-23 | 1995-06-30 | Sanofi Elf | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
CA2106642C (en) * | 1992-10-14 | 2005-08-16 | Peter Bod | Carbazolone derivatives and process for preparing the same |
FR2714057B1 (en) | 1993-12-17 | 1996-03-08 | Sanofi Elf | New derivatives of 3-pyrazolecarboxamide, process for their preparation and pharmaceutical compositions containing them. |
US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
FR2741621B1 (en) | 1995-11-23 | 1998-02-13 | Sanofi Sa | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2742148B1 (en) | 1995-12-08 | 1999-10-22 | Sanofi Sa | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2758723B1 (en) | 1997-01-28 | 1999-04-23 | Sanofi Sa | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS |
FR2761266B1 (en) | 1997-03-28 | 1999-07-02 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES |
FR2789079B3 (en) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
FR2800375B1 (en) * | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | TRICYCLIC DERIVATIVES OF PYRAZOLECARBOXYLIC ACID, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2800372B1 (en) * | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | TRICYCLIC DERIVATIVES OF 1-BENZYLPYRAZOLE-3- CARBOXYLIC ACID, THEIR PREPARATION, THE MEDICINAL PRODUCTS CONTAINING THEM |
FR2804604B1 (en) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF USEFUL DRUGS TO FACILITATE THE STOPPAGE OF TOBACCO CONSUMPTION |
FR2809621B1 (en) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES SUITABLE AS ANTIDIARRHOISTS |
FR2816938B1 (en) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | 3-AROYLINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
JP2005507875A (en) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | Novel pyrazole analogues acting on cannabinoid receptors |
DK1429761T3 (en) | 2001-09-21 | 2007-02-05 | Solvay Pharm Bv | New 4,5-dihydro-1H-pyrazole derivatives with CB1 antagonistic effect |
KR100950430B1 (en) | 2001-09-21 | 2010-04-02 | 솔베이 파마슈티칼스 비. 브이 | 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
JP2005526730A (en) * | 2002-02-19 | 2005-09-08 | ファルマシア・コーポレーション | Tricyclic pyrazole derivatives for the treatment of inflammation |
ITMI20041033A1 (en) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | PHARMACEUTICAL COMPOUNDS |
US8030345B2 (en) * | 2004-07-12 | 2011-10-04 | Cadila Healthcare Limited | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
-
2005
- 2005-07-08 US US11/632,236 patent/US8030345B2/en not_active Expired - Fee Related
- 2005-07-08 KR KR1020077000654A patent/KR20070041717A/en not_active Application Discontinuation
- 2005-07-08 MX MX2007000491A patent/MX2007000491A/en not_active Application Discontinuation
- 2005-07-08 NZ NZ580387A patent/NZ580387A/en not_active IP Right Cessation
- 2005-07-08 CN CNA200580030114XA patent/CN101014605A/en active Pending
- 2005-07-08 NZ NZ552670A patent/NZ552670A/en not_active IP Right Cessation
- 2005-07-08 AP AP2007003880A patent/AP2228A/en active
- 2005-07-08 EP EP10182912A patent/EP2343302A1/en not_active Withdrawn
- 2005-07-08 JP JP2007520976A patent/JP2008505965A/en not_active Withdrawn
- 2005-07-08 GE GEAP20059851A patent/GEP20094682B/en unknown
- 2005-07-08 UA UAA200700981A patent/UA88910C2/en unknown
- 2005-07-08 WO PCT/IN2005/000237 patent/WO2006025069A2/en active Application Filing
- 2005-07-08 BR BRPI0513104-9A patent/BRPI0513104A/en not_active IP Right Cessation
- 2005-07-08 AU AU2005278781A patent/AU2005278781B2/en not_active Ceased
- 2005-07-08 CA CA2586011A patent/CA2586011C/en not_active Expired - Fee Related
- 2005-07-08 EA EA200700246A patent/EA011307B1/en not_active IP Right Cessation
- 2005-07-08 EP EP05815697A patent/EP1781668A2/en not_active Withdrawn
-
2007
- 2007-01-05 ZA ZA200700162A patent/ZA200700162B/en unknown
- 2007-01-10 IL IL180637A patent/IL180637A0/en unknown
- 2007-01-11 TN TNP2007000006A patent/TNSN07006A1/en unknown
- 2007-01-12 EC EC2007007167A patent/ECSP077167A/en unknown
- 2007-01-17 NO NO20070299A patent/NO20070299L/en not_active Application Discontinuation
-
2010
- 2010-04-29 US US12/769,861 patent/US20100273791A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9944606B2 (en) | 2009-08-28 | 2018-04-17 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US11746091B2 (en) | 2009-08-28 | 2023-09-05 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US11214548B2 (en) | 2009-08-28 | 2022-01-04 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US8778950B2 (en) | 2009-08-28 | 2014-07-15 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US10183930B2 (en) | 2011-02-25 | 2019-01-22 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
US9867822B2 (en) | 2011-02-25 | 2018-01-16 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US10632134B2 (en) | 2011-02-25 | 2020-04-28 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US10981895B2 (en) | 2011-02-25 | 2021-04-20 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
US9492447B2 (en) | 2011-02-25 | 2016-11-15 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US11560369B2 (en) | 2011-02-25 | 2023-01-24 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
US9458136B2 (en) | 2011-02-25 | 2016-10-04 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
US11771695B2 (en) | 2011-02-25 | 2023-10-03 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US11084789B2 (en) | 2016-01-14 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US8030345B2 (en) | 2011-10-04 |
CA2586011C (en) | 2011-07-19 |
WO2006025069A8 (en) | 2007-03-15 |
BRPI0513104A (en) | 2008-04-29 |
CN101014605A (en) | 2007-08-08 |
UA88910C2 (en) | 2009-12-10 |
CA2586011A1 (en) | 2006-03-09 |
MX2007000491A (en) | 2007-03-28 |
US20100273791A1 (en) | 2010-10-28 |
US20080051386A1 (en) | 2008-02-28 |
WO2006025069A3 (en) | 2006-04-27 |
IL180637A0 (en) | 2007-06-03 |
EA200700246A1 (en) | 2007-08-31 |
ECSP077167A (en) | 2007-05-30 |
NZ552670A (en) | 2010-02-26 |
ZA200700162B (en) | 2009-09-30 |
NO20070299L (en) | 2007-03-26 |
EP2343302A1 (en) | 2011-07-13 |
AU2005278781A1 (en) | 2006-03-09 |
AP2007003880A0 (en) | 2007-02-28 |
GEP20094682B (en) | 2009-05-10 |
TNSN07006A1 (en) | 2008-06-02 |
EP1781668A2 (en) | 2007-05-09 |
EA011307B1 (en) | 2009-02-27 |
AU2005278781B2 (en) | 2009-06-18 |
AP2228A (en) | 2011-04-01 |
NZ580387A (en) | 2011-06-30 |
JP2008505965A (en) | 2008-02-28 |
KR20070041717A (en) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100273791A1 (en) | Tricyclic pyrazole derivatives as cannabinoid receptor modulators | |
CA2616451C (en) | Substituted benzyl derivatives as gsk-3 inhibitors | |
CA2633440C (en) | 1,3-dioxane carboxylic acids | |
AU2018236290B2 (en) | MK2 inhibitors, synthesis thereof, and intermediates thereto | |
CA2555817A1 (en) | 1 , 3 - dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | |
WO2009116074A2 (en) | Substituted benzimidazoles as cannabinoid modulator | |
CA2508574A1 (en) | 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | |
CA2545711A1 (en) | Urea derivatives as kinase modulators | |
AU2007309567A1 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
Oka et al. | Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1, 2, 4-oxadiazol-5-yl]-4-methyl-1, 3-thiazol-2-yl} acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases | |
US20220033436A1 (en) | Derivative of sarsasapogenin, pharmaceutical composition and use thereof | |
WO2005077937A1 (en) | Substituted hydroxamic acid derivatives as tnf inhibitors | |
AU2006212209B2 (en) | [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular | |
US20100240709A1 (en) | Sulfoximine Derivatives as p38 MAP Kinase Inhibitors | |
KR20130042565A (en) | Benzofuranone compound and pharmaceutical composition containing same | |
US20060194846A1 (en) | [1,2,4]-Dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular | |
WO2008062424A2 (en) | Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators | |
WO2011048936A1 (en) | Aminothiazole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2586011 Country of ref document: CA Ref document number: 2005278781 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700162 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007520976 Country of ref document: JP Ref document number: 180637 Country of ref document: IL Ref document number: 1020077000654 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/000491 Country of ref document: MX Ref document number: 12007500129 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552670 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005815697 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200700232 Country of ref document: VN Ref document number: 200700246 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2005278781 Country of ref document: AU Date of ref document: 20050708 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005278781 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9851 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580030114.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005815697 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11632236 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11632236 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0513104 Country of ref document: BR |